

CooperCompanies

Investor Presentation

February 29, 2024

CooperVision® CooperSurgical®

Cautionary Statements

Forward-Looking Statements

This presentation and management's discussion of our results and outlook contain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements that are other than statements of historical fact are forward looking. To identify these statements, look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward looking statements include our financial guidance for fiscal year 2024 and all statements regarding strategic and operational plans, launches of and prospects for new products and services, anticipated growth in market share and sales, market and industry trends and drivers, including market growth expectations, a planned stock split and other planned corporate and commercial transactions, and ESG initiatives. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the "Forward-Looking Statements" section in our press releases and under the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com. Such risk factors include the adverse impact of global business and economic conditions (such as military conflicts, inflation, and currency exchange rate and interest rate fluctuations), risks associated with international operations, risks related to pending and completed transactions, evolving global regulatory requirements, and operational challenges. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Non-GAAP Financial Measures

Certain financial measures included in this presentation, or which may be referred to in management's discussion of our results and outlook, are non-GAAP measures that we believe are helpful in understanding our results. These non-GAAP financial measures may include, for example, constant currency and organic revenue growth, non-GAAP earnings per share and non-GAAP margin results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. The reasons that we use these non-GAAP measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section of our earnings press releases, copies of which are available on the Company's website at <https://investor.coopercos.com/press-releases>. With respect to guidance, we have not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measure. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, we are not able to provide such reconciliations.

Trademarks

CooperVision, CooperSurgical, and other trade names, trademarks or service marks of Cooper and its subsidiaries appearing in this report are the property of Cooper and its subsidiaries. Trade names, trademarks and service marks of the other companies appearing in this report are the property of their respective holders.

CooperCompanies - A Leading Global Medical Device Company

Improving lives one person at a time


Industry-leader
in Vision and
Women's Health

Publicly traded
Nasdaq: **COO**


Member of **S&P**
500 since 2016

FY23 Revenue ~\$3.6B

Business Unit



Geography



50M+ people
benefiting from our
products

130+ countries
where our
products are sold

15,000+ global
workforce


Operating in two growing markets with strong tailwinds



CooperCompanies

CooperCompanies

Total revenue more than doubled over the last ten years and reached a record high of almost \$3.6B in fiscal 2023



CooperCompanies

Fiscal 2024 financial guidance

		FY24 Guidance*	Organic Growth vs. FY23
Sales	Total	\$3,847 - \$3,897	7% - 8%
	CooperVision	\$2,573 - \$2,604	8% - 9%
	CooperSurgical	\$1,274 - \$1,293	5% - 7%
EPS	Non-GAAP	\$3.50 - \$3.58	

Notes: Sales \$ in millions

Organic growth excludes the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures, or discontinuations that occurred in the comparable period. A reconciliation of non-GAAP measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on our website: www.coopercos.com. With respect to EPS guidance, the Company has not provided reconciliation to GAAP due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, we are not able to provide such guidance.

*Guidance raised 2/29/24.



CooperCompanies

CooperCompanies

Long term strategy to execute on strategic goals and drive shareholder value



Drive Sustainable Revenue Growth

- Invest in and drive organic growth and gain market share – manufacturing expansion, distribution upgrades, R&D, new innovative products and services
- Strategic acquisitions that optimize portfolio



Deliver Profitability & Leverage

- Grow EPS faster than revenue – leverage investments and drive continuous improvements
- Organizational discipline and rigor to manage macroenvironmental challenges and disruptions that may arise



Stewards of Investor Capital

- Build for the long-term – invest in global infrastructure, manufacturing and distribution
- Disciplined capital allocation strategy – pay down debt, highly strategic accretive M&A, opportunistic share repurchases



Foster Culture & Community

- Strong global culture where we live our core values and further our mission to improve the lives of customers and patients
- Invest in employees



CooperVision

A global leader dedicated to helping improve the way people see each day



CooperVision®
Live Brightly®




Brand leadership across product portfolio


Global Soft Contact Lens Market

\$10+ billion high growth market

Market by Competitor



Market by Category



High Barriers to Entry

- High capital outlay with highly specialized manufacturing
- Technological know-how
- Stringent FDA and worldwide regulation
- Long history of product innovation

Favorable Industry Characteristics


- Strong fundamental growth drivers
- Underlying wearer growth
- Limited reimbursement risk
- Recession resistant
- Annuity business (durable)

Contact Lens Market Drivers

Strong fundamental growth drivers

- Growing global wearer base
 - Growing prevalence of myopia
 - Geographic expansion – low emerging market penetration
- New fits/trade-up
 - Shift into 1 Day Silicone Hydrogel lenses
 - Growth in Torics and Multifocals
- Higher global net pricing

Worldwide Prevalence of Myopia



Related risks:

- Impact to quality of everyday life
- Impaired learnings and development
- Long-term ocular health issues



CooperCompanies

Source: Management estimates and independent market research


CooperVision

A long history of success both in sales and market share growth




Durable Sales Growth

Annual Sales



Outpacing Market Growth

Market Share



CooperCompanies

Note: Sales \$ in millions
Source: Management estimates and independent market research

CooperVision

Global Market Leader in Myopia Control and Myopia Management



Soft contact lenses

MiSight® 1 day

- First and only FDA approved contact lens for **myopia control**
- Backed by extensive 7-year clinical data

Freedom from spectacles



Orthokeratology



- Broad range of market-leading Ortho-k lenses

Spectacles and contact lens free during the day



Spectacle lenses



- **Myopia management** spectacles
- JV relationship with EssilorLuxottica
- Launched in China, Canada, the Netherlands, the UK, and Israel
- FDA granted SightGlass spectacles “Breakthrough Device Designation.”

An easy start to myopia management



CooperCompanies Comprehensive portfolio of science-based treatment options to help reduce the progression of myopia in children

CooperVision

Well positioned to succeed



Products



Best-in-class products

Broadest product portfolio

Innovative products

Strength in **premium toric** and **multifocal** products

Broadest SKU Range

New higher-value products launching around the world

Winning **new wearers**

Customer Support



Branded and customer brands

Manufacturing, packaging, and distribution **excellence**

Differentiated Value-Added Services

Outstanding customer experience

Relationships



Large **global** footprint

Strong **key account** relationships and longer-term contracts

Strong relationships with independent practitioners, distributors, retailers and online




Cooper**Companies**

CooperSurgical

Healthy women, babies, and familiesTM



FY23 Revenue \$1.17B



CooperSurgical

One of the fastest growing, most innovative fertility companies in the world



Fertility Business Highlights

- Broadest portfolio in the fertility industry¹ that includes:
 - Consumables
 - Capital equipment
 - Reproductive genetic testing
 - Egg & sperm donation
 - Cryopreservation
- Investing in geographic expansion, key accounts, infrastructure build-out, and R&D



CooperCompanies

Industry Highlights

>\$2B

Global
Market¹

5-10%

Annual
Growth²

- Roughly **1 in 6** people have experienced infertility at some stage in their lives, globally³
- Over **1M** babies are born annually from assisted reproductive technology cycles⁴
- The underlying cause of infertility is **1/3** women, **1/3** men, and **1/3** a combination of the two, or unknown⁴

Growth Drivers

- Women delaying childbirth
- Increasing patient awareness
- Improved product offerings such as cryopreservation services and increasing fertility benefits coverage
- Technology improvements for both male and female infertility challenges
- Improving access to treatment
- Growth in the number of fertility clinics
- Greater worldwide disposable income

Source: 1. Manufacturer sales of medical device products and services excluding consultation and pharma
2. BTIG, LLC. (2020, October). Assisted Reproductive Technologies, p. 7
3. The World Health Organization (WHO)
4. European Society for Human Reproduction and Embryology (ESHRE)

CooperSurgical

Extensive office and surgical platform



CooperSurgical®



Endosee®
Advance

Paragard®
intrauterine copper contraceptive



INSORB®
Subcuticular Skin Stapler

ALLY II UPS™
by CooperSurgical®

Office and Surgical Business Highlights

- Office and surgical includes medical devices, stem cell storage, and Paragard.
- Acquired select Cook Medical assets focused primarily on obstetrics, doppler monitoring and gynecology surgery (11/1/23).
- Produce over 600 clinically-relevant medical devices used by women's health care providers in gynecology and obstetrics.
- Paragard is the only FDA-approved non-hormonal IUD. It is placed in office and is 99% effective with a ten-year indication.



CooperCompanies

CooperSurgical

Office and surgical growth drivers



Medical Device

- Positive procedure volume and strength in core products
- Shifting to minimally invasive procedures
- Reimbursement is designed to drive procedures to the office
- Health systems are looking for partnership relationship with vendors



Stem Cell Storage

- Advancing stem cell research and therapies increase potential value of storage
- Cord blood is standard of care alternative to bone marrow transplants for blood disorders¹
- Regenerative Medicine potential applications rapidly emerging (lung disease, sports injury, etc.) with 1K+ ongoing clinical studies²




CooperCompanies

Source: 1. Chao, N. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. In: UpToDate. Negrin, R (Ed). UpToDate, Waltham, MA.
2. <https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/> Accessed Nov 10, 2021



Durable Sales Growth

Annual Sales



CooperCompanies

Conducting business in a socially and environmentally responsible manner is important to our long-term business success and the future of our planet

ENVIRONMENT

Pushing boundaries, working with partners, and doing what's necessary to protect the planet.



8 facilities LEED® or BREEAM® certified



Prevented the equivalent of more than 100 million plastic bottles from polluting the ocean through our focus on plastic neutrality*



100% renewable electricity sourcing at all key facilities in New York and the United Kingdom



Awarded a U.S. patent for a light-weight contact lens blister pack that uses **~30% less plastic**



Reduced our GHG emissions by **more than 7%** while manufacturing more products than ever

SOCIAL

Supporting an inclusive, healthy, and safe work environment that engages and empowers our employees to develop life-changing solutions for the customers we serve.



Women made up **49%** of our global workforce



Scored **100%** on the Human Rights Campaign Foundation's 2022 Corporate Equality Index



\$1.5 million raised to date for Optometry Giving Sight, providing **eye exams for 300,000 people**



Named Top 10 Best Large Workplace in Manufacturing and Production in the U.S. by *Fortune* magazine



Continuing our **\$2M investment** in talent development through 2024

GOVERNANCE

Upholding strong governance and high standards of ethics, compliance, and accountability to provide long-term value for our shareholders, customers, employees, and communities.



50% Board gender diversity



\$0 monetary losses as a result of legal proceedings associated with bribery and corruption or false marketing claims



Strong information security and data privacy governance and risk management



Executive Leadership participation in ESG and a dedicated cross-functional ESG team; the Board of Directors **oversees ESG topics**

Note: * Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram (kg) of plastic that may reach or be destined for waterway. CooperVision purchases credits equal to the weight of plastic in participating brand orders in a specified time period. Plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g., ink). For calculation purposes, Plastic Bank uses 1 kg of plastic to equal 50 bottles.

Source: CooperCompanies' 2022 ESG Report

CooperCompanies

Driving Long Term Sustainable Value

